Biovica International Ab Class B · OMXSTO:BIOVIC_B

Biovica International Ab Class B — Q1 2025 Earnings Presentation

31 slides from Biovica International Ab Class B's earnings presentation, Sep 12, 2024

1. Slide 1: Biovica International AB

   ©2024 ©2023 Biovica International AB

2. Slide 2: Forward Looking-Statements Disclaimer

   Forward Looking-Statements Disclaimer The Investor Presentation may contain certain statements that are forward-looking. These statements may refer in particular to the Company’s business strategies, its expansion and growth of operations, future events, trends or objectives and expectations, which

3. Slide 3: Q1 Interim Report

   Q1 Interim Report Anders Rylander CEO Anders Morén CFO Hector Tamburini Head of US Operations Henrik Winther SVP Business Development 3 ©2024 Biovica International AB

4. Slide 4: Agenda

   Agenda Biovica Introduction Q1 Highlights Financial Update US Update Pharma Services Summary and Q&A ©2023 Biovica International AB – Proprietary and Confidential. ©2024 ©2023 All rights reserved. Biovica International AB

5. Slide 5: Q&A Session

   Q&A Session Financial Analysts on today’s call: • Johan Unnérus - RedEye • Chien-Hsun Lee & Dan Akschuti - Pareto Securities AG • Luísa Morgado – van Lanschot Kempen ©2024 5 Biovica International AB

6. Slide 6: Biovica Introduction

   Biovica Introduction ©2024 ©2023 Biovica International AB

7. Slide 7: DiviTum TKa

   DiviTum® TKa An early indicator of cancer treatment effectiveness + References: http://biovica.com/technology/publications/ DiviTum® TKa cell proliferation provides quicker evaluation of cancer treatment efficacy. ©2024 Biovica International AB

8. Slide 8: Validated by a wealth of scientific evidence

   Validated by a wealth of scientific evidence 30+ published and peer-reviewed articles Cancer Area Patients Nr. of studies Strong evidence supporting the use of Breast Cancer 3,039 14 DiviTum® TKa as a clinical biomarker Gastrointestinal 713 4 of CDK4/6i response Malignant Melanoma 86 2 Collaboration

9. Slide 9: Stepwise launch plan for realizing huge potential!

   Stepwise launch plan for realizing huge potential! ©2024 Biovica International AB

10. Slide 10: Q1 Highlights

    Q1 Highlights 10 ©2024 ©2023 Biovica International AB

11. Slide 11: Q1 Highlights

    Q1 Highlights US: • Q1 sales are up ~50% vs Q4! • Increase on existing accounts, several new institutions & prescribers Pharma Services: • Positive development of the business with high demand and growth • Two projects delayed by customers pushed revenues forward to Q2 Financials: • Improved operati

12. Slide 12: Q1 2024/2025 Significant Events

    Q1 2024/2025 Significant Events Significant events during the Q1 (May-July) • DiviTum TKa results presented at ASCO, the world’s largest cancer conference • Biovica signed a new drug development agreement • The extraordinary general meeting of Biovica International AB resolved to implement new incen

13. Slide 13: Financial Update - Q1 2024/2025

    Financial Update - Q1 2024/2025 13 ©2024 ©2023 Biovica International AB

14. Slide 14: Q1 Net Sales by product group 23/24 vs 24/25 (kSEK)

    Q1 Net Sales by product group 23/24 vs 24/25 (kSEK) 2000 1 766 1 714 1800 1600 518 1400 961 1200 Q1 US Sales significant increase 1000 569 balanced off with 800 delays in sample delivery (Clinical 600 Trial delay) from 400 793 some Pharma 627 Service Customers 200 (Tests & Kits) 0 13 Q1 23/24 Q1 24/

15. Slide 15: US IVD Sales growth continues!

    US IVD Sales growth continues! Sales by Quarter (US$) $70 000 $60 000 $58 611 $50 000 +48% $39 603 $40 000 $30 000 $20 000 $10 000 $- Q1 23/24 Q2 23/24 Q3 23/24 Q4 23/24 Q1 24/25 • US IVD Net Sales Q4: 23/24 US$ 39,6K • US IVD Net Sales Q1: 24/25 US$ 58,6K 48% Q/Q Growth ©2024 Biovica International

16. Slide 16: Cash Position by quarter (MSEK)

    Cash Position by quarter (MSEK) 120,00 100,00 80,00 65,2 60,00 40,00 20,00 - Q1 Q2 Q3 Q4 Cash 2023/2024 Cash 2024/2025 ©2024 Biovica International AB

17. Slide 17: Significant improvement in Cash flow

    Significant improvement in Cash flow - Q1 23/24 vs 24/25 Q1 23/24 Q1 24/25* 5 SEK Millions -5 - 10 - 22 - 15 - 30 - 20 - 25 - 21 - 30 - 35 *Q1 24/25 change in working - 40 capital adjusted for Re-Org from - 38 Q4 23/24 (MSEK 8) 8,5) - 45 Operating Cash flow before change in Working Capital Change in

18. Slide 18: Q1 FY 2024-25: US Business Update

    Q1 FY 2024-25: US Business Update September 2024 ©2024 ©2023 Biovica International AB

19. Slide 19: Agenda

    Agenda Sales Performance Advisory Boards Moving Forward Clinical Trial Activities New Opportunities ©2024 Biovica International AB

20. Slide 20: Sales Performance

    Sales Performance Sales Performance IVD Tests (US) Sales by Quarter $70 000 Revenue growth is 48% Q1 vs Q4! $58 611 $60 000 20% growth in ordering institutions over Q4 $50 000 $39 603 $40 000 32% new prescribers ordered DiviTum $30 000 $27 833 $20 000 $10 000 $5 020 $1 145 $- Q1 23/24 Q2 23/24 Q3 23

21. Slide 21: Advisory Board Concept successfully expands business!

    Advisory Board Concept successfully expands business! Key Opinion Leaders (KOL) share real-world experience in using DiviTum TKa to follow therapy and determine prognosis in MBC Creates powerful messaging about DiviTum TKa capabilities Provides valuable customer feedback, improves our strategy and p

22. Slide 22: Moving forward – Initiatives for Accelerated Growth!

    Moving forward – Initiatives for Accelerated Growth! Grow current accounts – More prescribers from existing institutions Add new accounts – Focus on IDN* and big institutions (cancer centers) Facilitate ordering process – reduce administrative burden, link Biovica’s LIS with customers EMR/EHR *Integ

23. Slide 23: Interventional & Observational Clinical Trial Activities

    Interventional & Observational Clinical Trial Activities - generate revenues and additional evidence! Drug to Drug Interaction and Dose Reduction CD4/6 Inhibition in HR+ MBC Prospective Interventional Trial - recruiting patients DiviTum®TKa: A Biomarker Assay for Prediction of Treatment Efficacy and

24. Slide 24: Progressing clinical adoption and revenue growth

    Progressing clinical adoption and revenue growth San Antonio Breast Cancer Inclusion in NCCN Guidelines Symposium (Dec 2024) Potential for 6 abstracts including Target end of 2025 DiviTum® TKa to be selected and Based on clinical trials and real-world presented at symposium experience Large Ad Board

25. Slide 25: Pharma Services Update

    Pharma Services Update 25 ©2024 ©2023 Biovica International AB

26. Slide 26: The Pharma Services & Collaboration Business

    The Pharma Services & Collaboration Business Onboarding of new biopharma customers continue according to plan 1. Service & Kit Sales 2. CDx Collaborations 3. CDx Product Sales Services under TESA* or MSA** CDx Development under DCA*** CDx product on the market (Multiple projects/MSA) Collaboration f

27. Slide 27: Highlights

    Highlights Q1: • One new MSA signed (PR’ed 28/6) • Two new MSA’s in negotiations • One is expected to be signed in near future. Includes a significant WO • One MSA amended with another 2.5 years • We signed an NDA with a TIER-1* US pharma company • We initiated TKa-service discussions with yet anoth

28. Slide 28: Summary & QA

    Summary & QA ©2024 ©2023 28 Biovica International AB

29. Slide 29: Summary & Targets

    Summary & Targets Progress made during Q1 Measures cell proliferation from a simple blood sample US: Sales development continues – 48% up since previous DiviTum® TKa addresses an important clinical unmet need quarter Pharma Services: Demand for services, additional agreement Supported by cancer KOLs

30. Slide 30: Q&A Session

    Q&A Session Financial Analysts on today’s call: • Johan Unnérus - RedEye • Chien-Hsun Lee & Dan Akschuti - Pareto Securities AG • Luísa Morgado – van Lanschot Kempen ©2024 30 Biovica International AB

31. Slide 31: Biovica International AB

    31 ©2024 Biovica International AB

Biovica International — Q1 2025 Earnings Presentation on 6ix